The FDA has received 7,776 adverse event reports for dogs that name Grapiprant.
- 7,776 reports name Grapiprant in dogs, which is 0.8% of all 1,001,380 dog reports. A report counts under every active ingredient it names.
- 30% are marked serious and 10.0% record a death or euthanasia; across all dog reports those figures are 29% and 5.4%.
- 17% are complaints that the product did not work (38% across all dog reports).
- The clinical signs reported most are vomiting, diarrhoea and lack of efficacy.
- The FDA lists 1 approved animal drug application containing Grapiprant for dogs, the earliest approved in 2016.
- None of this is a rate. The FDA data does not record how many dogs were given Grapiprant, so it cannot say how often any of this happens.
How the reports break down
| What the reports say | Reports | Share of this medicine's reports | All dog reports |
|---|---|---|---|
| Marked seriousthe FDA record flags the report as serious | 2,367 | 30% | 29% |
| Death or euthanasiathe outcome recorded in the report, with no finding of cause | 775 | 10.0% | 5.4% |
| Did not worka complaint that the product failed to work, which the FDA files as an adverse event | 1,290 | 17% | 38% |
| Seizurea seizure or convulsion is among the clinical signs | 301 | 3.9% | 4.4% |
| Not used per labelthe report says the product was not used the way its label directs | 2,563 | 33% | 21% |
Where on the body do the reported signs sit?
Not on the body: Whole body 16% Did not work 8.8%
- Stomach and gut45%vomiting, diarrhoea, not eating, decreased appetite and 4 more
- Blood and organ tests20%elevated alanine aminotransferase (alt), elevated blood urea nitrogen (bun), elevated serum alkaline phosphatase (sap), elevated creatinine and 3 more
- Whole body16%lethargy, death by euthanasia, lethargy, death
- Did not work8.8%lack of efficacy
- Brain and nerves4.4%seizure, ataxia
- Heart and breathing2.7%panting
- Behaviour2.5%behavioural disorder
- Thirst and urination1.7%polydipsia
Each figure is a share of sign mentions among the 25 signs reported most for Grapiprant in dogs. One report can list several signs, so these do not add up to reports. The grouping into body systems is ours; the signs in each group are listed beside it.
Clinical signs reported most
- Vomiting1,468 19%
- Diarrhoea1,302 17%
- Lack of efficacy978 13%
- Lethargy658 8.5%
- Elevated alanine aminotransferase (ALT)521 6.7%
- Death by euthanasia492 6.3%
- Not eating490 6.3%
- Decreased appetite443 5.7%
Reports received per year
Is it approved for dogs?
The FDA lists 1 approved animal drug application containing Grapiprant for dogs, the earliest approved in 2016.
| Product | Form | Approved for | First approved | FDA application |
|---|---|---|---|---|
| GalliprantElanco US Inc. | Tablet RX | Dog | 2016 | 141-455 |
From the FDA record for Galliprant: For oral use in dogs only.
What can you do next?
Report counts: FDA Center for Veterinary Medicine adverse event reports, read 11 November 2026 (FDA data last updated 5 October 2026). Approvals: Animal Drugs @ FDA, read 11 November 2026. Counts are reports, not animals and not doses.
Where can you go from this result?
This result is one of 94 in the lookup. Open it in the lookup to set it beside another medicine, or read how the counts were collected.
- Firocoxib in dogs8,009
- Meloxicam in dogs8,083
- Amoxicillin in dogs6,749
- Febantel in dogs6,733
To report a suspected side effect in your own animal, follow how to report an animal drug side effect to the FDA. The FDA explains what a report can and cannot show in openFDA's guide to reading the results.
Compiled by Vincent Wesley Couey, PetMaxxing Research (ORCID 0009-0005-6869-308X). Sources: openFDA animal and veterinary adverse event interface; Animal Drugs @ FDA.